is compound semaglutide as effective as ozempic FDA issues warning about some compounded versions of for diabetes, weight loss The Pros and Cons of

Smaller production batches, stricter quality control thresholds, and limited commercial-scale manufacturing (Eli Lilly holds the investigational new drug status) keep per-milligram costs elevated compared to more widely synthesised analogs

FDA does not review compounded medications for safety or efficacy

Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a Meta-analysis of the EXSCEL and FIGHT trials

Research has demonstrated superior weight reduction outcomes compared to dual-agonist peptides, with subjects showing significant reductions in body fat, improved insulin sensitivity, and favourable changes in lipid profiles